Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies March 30, 2018
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Ferring Pharmaceuticals January 22, 2018
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging January 18, 2018
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals January 11, 2018
Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments October 4, 2017